A Brief History of CEL-SCI Corporation (CVM)

CEL-SCI Corporation (CVM) is a biotechnology company based in Vienna, Virginia, that is focused on the development of immunotherapy products for the treatment of cancer and other diseases.

The company was founded in 1983 by Geert Kersten and Maximilian de Clara. Since its inception, CEL-SCI has been dedicated to harnessing the power of the immune system to fight diseases.

• Multikine: One of the company's most important products is Multikine, a therapeutic vaccine for the treatment of head and neck cancer. This product has been in development for many years and has shown promising results in clinical trials.
• LEAPS Technology: CEL-SCI is also known for its patented LEAPS (Ligand Epitope Antigen Presentation System) technology, which allows for the development of novel vaccines and immunotherapies.
• Global Reach: The company has a global reach, with research and development activities taking place in various countries around the world.

Who Owns CEL-SCI Corporation (CVM)

CEL-SCI Corporation (CVM) is a biotechnology company based in Virginia, USA. The ownership of the company is spread out among institutional investors and individual shareholders. As of the latest available data, the majority of CEL-SCI's shares are held by institutional investors.

Some of the key institutional investors that own shares in CEL-SCI Corporation include:

• RA Capital Management: RA Capital Management is a prominent healthcare-focused investment firm that holds a significant stake in CEL-SCI.
• Vanguard Group: The Vanguard Group is one of the largest investment management companies in the world and is also a major shareholder in CEL-SCI Corporation.
• BlackRock: BlackRock is another major institutional investor that owns shares in the company.

In addition to institutional investors, CEL-SCI Corporation also has a significant number of individual shareholders who own smaller stakes in the company. These individual shareholders include retail investors and company insiders.

Overall, the ownership of CEL-SCI Corporation is diversified among various institutional investors and individual shareholders, each contributing to the company's shareholder base.

CEL-SCI Corporation (CVM) Mission Statement

At CEL-SCI Corporation (CVM), our mission is to develop and commercialize innovative immunotherapy products for the treatment of cancer and other diseases. We are committed to leveraging the power of the immune system to improve patient outcomes and quality of life.

Our core values guide our work and set us apart in the industry:

• Innovation: We constantly strive to push boundaries and explore new possibilities in immunotherapy research.
• Compassion: We prioritize the well-being of patients and their families in everything we do.
• Integrity: We operate with honesty, transparency, and a commitment to ethical practices.
• Collaboration: We believe in the power of partnerships and teamwork to drive success and achieve our goals.

By staying true to our mission and values, CEL-SCI Corporation is dedicated to making a meaningful impact in the field of immunotherapy and improving the lives of patients around the world.

How CEL-SCI Corporation (CVM) Works

CEL-SCI Corporation (CVM) is a biotechnology company that focuses on the development and commercialization of immunotherapy products for the treatment of cancer and other diseases. The company's flagship product is Multikine, a therapeutic vaccine designed to stimulate the immune system to attack tumors.

CEL-SCI's approach to developing immunotherapy products involves leveraging the body's own immune system to target and destroy cancer cells. The company believes that this approach can be more effective and less toxic than traditional treatments such as chemotherapy and radiation therapy.

Key components of CEL-SCI's strategy include conducting clinical trials to test the safety and efficacy of its products, obtaining regulatory approval for commercialization, and forging partnerships with other organizations for distribution and marketing. The company also invests in research and development to continuously improve its products and explore new treatment options.

• Clinical trials: CEL-SCI conducts clinical trials to evaluate the effectiveness of its products in treating various types of cancer. These trials involve testing the safety and efficacy of the products in human patients to determine if they can be approved for commercial use.
• Regulatory approval: Once clinical trials have been completed, CEL-SCI seeks regulatory approval from government agencies such as the FDA to commercialize its products. This process involves submitting data from the trials to demonstrate the safety and efficacy of the products.
• Partnerships: CEL-SCI collaborates with other organizations, such as pharmaceutical companies and research institutions, to bring its products to market. These partnerships help the company reach a wider audience and expand its product offerings.
• Research and development: CEL-SCI invests in research and development to improve its existing products and develop new treatment options. This ongoing innovation is crucial for staying competitive in the rapidly evolving field of immunotherapy.

How CEL-SCI Corporation (CVM) Makes Money

CEL-SCI Corporation (CVM) makes money through various revenue streams related to its biotechnology products and services. Here are some of the key ways the company generates income:

• Multikine Product Sales: CEL-SCI's flagship product is Multikine, a immunotherapy treatment for head and neck cancer. The company earns revenue from the sales of Multikine to healthcare providers.
• Research and Development Grants: CEL-SCI receives funding from government agencies, non-profit organizations, and other sources to support its research and development efforts. These grants provide an important source of revenue for the company.
• Clinical Trials: CEL-SCI conducts clinical trials to test the safety and efficacy of its products. The company may receive funding from partners or government entities to conduct these trials, generating revenue in the process.
• Licensing Agreements: CEL-SCI may enter into licensing agreements with other companies to commercialize its technology or products. These agreements often involve upfront payments, royalties, or milestone payments, providing additional sources of income for the company.
• Intellectual Property: CEL-SCI holds patents and other intellectual property related to its products and technologies. The company may generate revenue through licensing its intellectual property to third parties.